Abstract
Purpose
The furosemide stress test is useful for predicting acute kidney injury (AKI) progression, but its widespread use is limited by concerns regarding adverse events associated with high-dose administration (1-1.5 mg/kg). Furosemide responsiveness (FR) to lower doses seems to have high predictive value while reducing such risks, but its utility in early-stage AKI (stage 1) is unclear. We thus investigated the predictive value of FR in early-stage AKI.
Methods
We retrospectively reviewed adult intensive-care unit patients (≥18 years old) admitted between January 2021 and June 2024 who received a furosemide bolus dose during stage 1 of AKI. FR was assessed using the FR index (FRI; 2-h urine output per furosemide dose), body weight-adjusted FRI (mFRI), and body weight-adjusted 2-h urine output (UO/BW). The indices were compared by the Mann–Whitney U test between progression (stage ≥2 within 7 days) and non-progression groups, and predictive ability was assessed by a receiver operating characteristic (ROC) analysis.
Results
Among 50 patients, 12 progressed and 38 did not. The mean furosemide dose was 0.29 mg/kg. FRI, mFRI, and UO/BW were significantly lower in the progression group (P < .001), with respective areas under the ROC curve of 0.945 (95% confidence interval, 0.887-1.000), 0.921 (0.831-1.000), and 0.919 (0.842-0.996). No hypotension requiring a rescue fluid bolus or other clinically overt hemodynamic instability was observed.
Conclusion
FR to lower doses was associated with subsequent progression from AKI stage 1 without evident hemodynamic instability in this cohort. These findings suggest that FR may provide a potentially safe and clinically useful indicator for early risk stratification in critically ill patients.
Keywords
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
